Press release
Replimune Group, Inc. (NASDAQ: REPL) Investor Alert: Deadline in Lawsuit on September 22, 2025
A Deadline is coming up on September 22, 2025 in the lawsuit for certain investors in Replimune Group, Inc. (NASDAQ: REPL).
Investors who purchased shares of Replimune Group, Inc. (NASDAQ: REPL) have certain options and there are strict and short deadlines running. Deadline: September 22, 2025. Replimune Group, Inc. (NASDAQ: REPL) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to the complaint filed in the U.S. District Court for the District of Massachusetts the plaintiff alleges on behalf of purchasers of Replimune Group, Inc. (NASDAQ: REPL) common shares between November 22, 2024 and July 21, 2025, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between November 22, 2024 and July 21, 2025, the misleading statements and/or failed to disclose that the Defendants recklessly overstated the IGNYTE trial's prospects, given material issues that defendants knew or should have known of, which resulted in the FDA deeming the IGNYTE trial inadequate and not well-controlled, and that as a result, defendants' statements about Replimune's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all times
Those who purchased shares of Replimune Group, Inc. (NASDAQ: REPL) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Replimune Group, Inc. (NASDAQ: REPL) Investor Alert: Deadline in Lawsuit on September 22, 2025 here
News-ID: 4176547 • Views: …
More Releases from Shareholders Foundation, Inc.
Investigation announced for Long-Term Investors in shares of 3D Systems Corporat …
An investigation was announced for current long-term investors in shares of 3D Systems Corporation (NYSE: DDD) concerning potential breaches of fiduciary duties by certain directors of 3D Systems Corporation.
Investors who are current long term investors in 3D Systems Corporation (NYSE: DDD) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors…
Fiserv, Inc. (NYSE: FI) Investor Alert: Deadline in Lawsuit on September 22, 202 …
A deadline is coming up on September 22, 2025 in the lawsuit filed for certain investors of Fiserv, Inc. (NYSE: FI) over alleged securities laws violations by Fiserv, Inc.
Investors who purchased shares of Fiserv, Inc. (NYSE: FI) have certain options and there are strict and short deadlines running. Deadline: September 22, 2025. Fiserv, Inc. (NYSE: FI) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -…
Investigation announced for Long-Term Investors in Rocket Pharmaceuticals, Inc. …
An investigation was announced for current long-term investors in shares of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) concerning potential breaches of fiduciary duties by certain directors of Rocket Pharmaceuticals, Inc..
Investors who are current long term investors in Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors…
Lawsuit filed for Investors who lost money with shares of LifeMD, Inc. (NASDAQ: …
An investor, who purchased shares of LifeMD, Inc. (NASDAQ: LFMD), filed a lawsuit over alleged violations of Federal Securities Laws by LifeMD, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of LifeMD, Inc. (NASDAQ: LFMD) have certain options and for certain investors are short and strict deadlines running. Deadline: October 27, 2025. NASDAQ: LFMD investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)…
More Releases for Replimune
Lawsuit filed for Investors who lost money with shares of Replimune Group, Inc. …
An investor, who purchased shares of Replimune Group, Inc. (NASDAQ: REPL), filed a lawsuit over alleged violations of Federal Securities Laws by Replimune Group, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Replimune Group, Inc. (NASDAQ: REPL) have certain options and for certain investors are short and strict deadlines running. Deadline: September 22, 2025. NASDAQ: REPL investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
Nonmelanoma Skin Cancer Market to Reach New Heights in Growth by 2034, DelveInsi …
The Key Nonmelanoma Skin Cancer Companies in the market include - Genentech, Sanofi, Sirnaomics, AiViva BioPharma, Replimune, Ortho Dermatologics, Philogen S.p.A., AstraZeneca, Pfizer, and others.
DelveInsight's "Nonmelanoma Skin Cancer Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Nonmelanoma Skin Cancer, historical and forecasted epidemiology as well as the Nonmelanoma Skin Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and…
Cutaneous Squamous Cell Carcinoma Treatment Market Size Report 2034 | Incyte Cor …
DelveInsight's "Cutaneous Squamous Cell Carcinoma Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of Cutaneous Squamous Cell Carcinoma (CSCC), historical and forecasted epidemiology as well as the Cutaneous Squamous Cell Carcinoma (cSCC) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Discover Key Insights into the Cutaneous Squamous Cell Carcinoma Market with DelveInsight's In-Depth Report @ Cutaneous…
Oncolytic Viruses Market Expected to rise, 2034 | Targovax, Replimune, Genelux C …
DelveInsight's report titled "Oncolytic Virus Market Size, Target Population, Competitive Landscape, and Market Forecast - 2034" provides a comprehensive analysis of Oncolytic Virus Therapies, including historical data, the competitive market, and market trends across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
The Oncolytic Viruses market growth is driven by factors like increase in the prevalence of Oncolytic Viruses, investments in research and development, entry…
Oncolytic Virus Therapies Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals …
Oncolytic Virus Therapy companies working in the market are Targovax, Replimune, Genelux Corporation, Candel Therapeutics, DNAtrix, SillaJen, Treovir, Lokon Pharma AB, Istari Oncology, CG Oncology, Amgen, Daiichio Sankyo and others.
(Albany, USA) DelveInsight's Oncolytic Virus Therapies Market Insights report includes a comprehensive understanding of current treatment practices, Oncolytic Virus Therapies emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the…
Nonmelanoma Skin Cancer Market to Exhibit Rapid Growth Rate During the Forecast …
DelveInsight's "Nonmelanoma Skin Cancer Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Nonmelanoma Skin Cancer, historical and forecasted epidemiology as well as the Nonmelanoma Skin Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Nonmelanoma Skin Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Nonmelanoma Skin Cancer…
